Catalyst Pharmaceuticals announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome, LEMS, Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the
Catalyst Pharmaceuticals announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome, LEMS, Awareness Day. This landmark event, now officially observed annually on March 30th, signifies a meaningful milestone for the
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult-to-treat diseases, today announced its endorsement of the inaugural Lambert-Eaton myasthenic syndrome (“LEMS”)
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, CEO of Catalyst, along with other members
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sutro Biopharma (STRO – Research Report) and Catalyst Pharma (CPRX – Research Report) with bullish sentiments.
Sutro Biopharma (STRO)
In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Sutro Biopharma, with a price target of $10.00. The company’s shares closed last Tuesday at $4.18.
According to TipRanks.com, Olson is a 5-star analyst with an average return of
Sutro Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $11.17, representing a 190.9% upside. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
Catalyst Pharma (CPRX)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma today and set a price target of $29.00. The company’s shares closed last Tuesday at $15.75.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of
Currently, the analyst consensus on Catalyst Pharma is a Strong Buy with an average price target of $25.37, a 58.6% upside from current levels. In a report issued on March 14, Citi also initiated coverage with a Buy rating on the stock with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STRO:
Meeting to be held in Denver/Chicago on March 18 hosted by Oppenheimer. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the